FDA launches Global Reliance Disclosure Program to share approval packages for foreign regulators' use
The programme lets applicants obtain minimally redacted FDA approval packages to support filings abroad, starting with PEPFAR tentative approvals and widening to novel drugs and biologics in January 2027.
The US Food and Drug Administration announced the Global Reliance Disclosure Program (GRDP) on 17 November 2026. Under it, the agency will share minimally redacted approval packages, including its detailed scientific and regulatory assessments, with applicants, who can then pass them to regulators outside the United States. FDA says the aim is to let those authorities rely on its review decisions rather than repeat product evaluations, while keeping sovereignty over their own regulatory decisions.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.